ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q1 2019

Strong sales growth during March; Zinzino based revenue increased 33% and the total group revenue with a total of 26% compared with the previous year. Zinzino based revenue for the first quarter 2019 increased with 26% and the total revenue with 19% compared with the first quarter the previous year.  

The revenue for Zinzino's sales markets increased by 33% to SEK 54.1 (40.8) million due to strong growth foremost in the other countries of Europe. Higher share of internal production during the month meant that Faun Pharma's external sales decreased by 33% and amounted to SEK 3.3 (4.8) million. Overall, the Group increased revenues by 26% to SEK 57.3 (45.6) million compared with the previous year.

The first quarter of 2019 became the strongest quarter in Zinzino based sales so far in the company's history; accumulated revenue January - March increased by 26% to MSEK 154.1 (122.4) compared with the previous year. Total revenue increased by 19% to MSEK 163.8 (137.5).

Revenues distributed as follows:

Regions, Msek 19-mar 18-mar Change Q1 2019 Q1 2018 Change
Nordic Markets 30.2 30.4 -1% 90.8 92.1 -1%
Baltic Markets 4.3 3.5 22% 13.3 10.8 23%
Europe Other Countries 17.8 5.3 235% 44.4 14.7 201%
North America 1.8 1.5 21% 5.6 4.7 18%
Zinzino 54.1 40.8 33% 154.1 122.4 26%
Faun Pharma 3.3 4.8 -33% 9.8 15.1 -36%
Zinzino Group 57.3 45.6 26% 163.8 137.5 19%

“We reflect on our strongest quarter in sales ever and we are ahead of our strategic target for average growth in sales in Zinzino for the period 2019-2021 as a minimum of 15 %”, says an inspired Dag Bergheim Pettersen, CEO Zinzino.

For more information please contact:
Dag Bergheim Pettersen, CEO Zinzino, tel. +47 (0) 932 25 700 zinzino.com

Pictures for free publication:
Marcus Tollbom, tel. +46 (0) 70-190 03 12

Certified Adviser:
Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se 

Tags:

About Us

Zinzino AB (publ.) is a direct sales company which operates through the EU, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns Norwegian BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has over 120 employees. The company has its registered office in Gothenburg, and offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public limited company and its shares are listed on Nasdaq First North.

Subscribe

Documents & Links